Viatris announces $6.94B in gross proceeds from remaining divestitures, achieving >12x multiple

Viatris Inc

Aggregated gross proceeds up to $6.94B from biosimilars, OTC, API, Women's Health, and non-core markets.
OTC offer: gross consideration up to ~$2.17B (12.8x multiple); API/Women's Healthcare: up to ~$1.2B (9.9x).
Strategic decision to retain Viagra, Dymista, select OTC in certain markets; retained value ~$1.6B.
Divestitures expected to close by end of H1 2024; net proceeds to be used for debt paydown targeting 3.0x gross leverage.
Up to 12 facilities and >6,000 employees (15% workforce) may be conveyed, simplifying organization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.